Latest Conference Articles

November 9th 2023, 9:47pm

Although advancements were “simple” to track for more than 40 years and left few questions open for evaluation in the ovarian cancer treatment paradigm, new questions have begun to develop surrounding the complexity of care.

November 9th 2023, 2:00pm

PER® Chemotherapy Foundation Symposium (CFS)

Gilles Salles, MD, PhD, expands on how data from recent clinical trials have helped shift the treatment paradigm for patients with diffuse large B-cell lymphoma.

November 9th 2023, 12:28am

PER® Chemotherapy Foundation Symposium (CFS)

Nicole Lamanna, MD, discusses treatment options for patients with chronic lymphocytic leukemia who develop resistance to a prior treatment.

November 8th 2023, 10:18pm

PER® Chemotherapy Foundation Symposium (CFS)

Along with the combination of venetoclax and obinutuzumab, the BTK inhibitor–based regimens of zanubrutinib monotherapy and acalabrutinib plus obinutuzumab represent the preferred options in the National Comprehensive Cancer Network Guidelines for the first-line treatment of patients with chronic lymphocytic leukemia without 17p deletions or TP53 mutations.

November 6th 2023, 9:18pm

LUGPA Annual Meeting

R. Jonathan Henderson, MD, discusses incorporating immunotherapy agents into practice in patients with bladder cancer.

November 6th 2023, 8:29pm

LUGPA Annual Meeting

Benjamin H. Lowentritt, MD, FACS, discusses the exploration of active surveillance in patients with prostate cancer.

November 3rd 2023, 9:39pm

LUGPA Annual Meeting

David Morris, MD, FACS, discusses the best practices for active surveillance in low- and intermediate-risk patients with prostate cancer, highlighting factors to look for in patients undergoing active surveillance that may point to the need for further treatment.

November 3rd 2023, 9:33pm

LUGPA Annual Meeting

E. David Crawford, MD, discusses the evolving role of active surveillance in patients with prostate cancer.

November 3rd 2023, 9:05pm

LUGPA Annual Meeting

Improved toxicity, advanced technology, and novel techniques have helped increase the use of radiotherapy for the treatment of different subgroups of patients with prostate cancer.

November 3rd 2023, 8:53pm

LUGPA Annual Meeting

Active surveillance can provide eligible patients with low-risk prostate cancer the opportunity to defer or avoid treatment and instead opt for routine monitoring of their disease; however, challenges arise when determining which patients should be eligible for this approach and how to maintain patient and provider protocol compliance.

November 3rd 2023, 8:43pm

LUGPA Annual Meeting

David Morris, MD, FACS, discusses the increasing the use of active surveillance in patients with low-risk prostate cancer and the goals of avoiding adverse effects associated with possible therapies.

November 3rd 2023, 4:30pm

LUGPA Annual Meeting

Gautam Jayram, MD, discusses the current indications for immunotherapy agents in the bladder cancer treatment paradigm, as well as immune-related adverse effects to be aware of when treating patients who are receiving these therapies.

November 3rd 2023, 3:12pm

LUGPA Annual Meeting

Gautam Jayram, MD, discusses current standards of care in the bladder cancer treatment arena, novel therapies under investigation in clinical trials that may expand the arsenal of available treatment strategies, and emphasizes the importance of implementing bladder cancer programs.

November 2nd 2023, 8:03pm

LUGPA Annual Meeting

Daniel Spratt, MD, discusses the expanded role of radiation therapy for the treatment of patients with prostate cancer, delves into the optimal approach for using radiation in tandem with hormonal therapy for these patients, and highlights ongoing research focused on minimizing adverse effects associated with radiotherapy.

October 31st 2023, 8:44pm

ESMO Congress

Combining sacituzumab govitecan-hziy and enfortumab vedotin-ejfv was safe, feasible, and produced high and early response rates in patients with treatment-resistant metastatic urothelial cancer.

October 27th 2023, 7:20pm

ESMO Congress

Pooled findings from exploratory analyses of the phase 2 DESTINY-Lung01 and DESTINY-Lung02 trials showed that different doses of fam-trastuzumab deruxtecan-nxki elicited similar intracranial responses in patients with HER2-mutated non–small cell lung cancer who had treated or untreated brain metastases at baseline.

October 26th 2023, 8:38pm

Bridging the Gaps in Lung Cancer

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

October 26th 2023, 6:50pm

ESMO Congress

Datopotamab deruxtecan elicited encouraging responses in patients with heavily pretreated non–small cell lung cancer harboring actionable genomic alterations.

October 24th 2023, 2:15pm

ESMO Congress

The intravesical chemotherapy delivery system TAR-200 provided sustained and durable responses in patients with Bacillus Calmette-Guérin–unresponsive, high-risk, non–muscle-invasive bladder cancer.

October 24th 2023, 4:00am

OncLive News Network: On Location at ESMO 2023

OncLive® will be LIVE with OncLive® News Network: On Location at the 2023 ESMO Congress. Each day, we will broadcast a series of interviews with top thought leaders, to learn their thoughts and reactions to data presented across oncology during the conference.